Vaccination against varicella?;Gegen varizellen impfen?

Monatsschrift fur Kinderheilkunde

Volumn 147, Issue 7, 1999, Pages 626-633

  Arndtz, Nathaly ^a   Schmitt, H J ^b  

^a SmithKline Beecham Pharma GmbH   (Germany)

^b NONE

Author keywords

Routine vaccination; Vaccination of risk groups use in Germany; Varicella; Varicella vaccine

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE;

ADULT; CHICKENPOX; DRUG COST; GERMANY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; INFECTION COMPLICATION; PATHOGENESIS; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; VARICELLA ZOSTER VIRUS;

EID: 0032811336     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001120050472     Document Type: Review

References (67)

1. American Academy of Pediatrics (1997) Varizella-zoster infections. In: Peter G (ed) Red book: report on the Comittee on Infectious Diseases. 24th edition. American Academy of Pediatrics, Elk Grove Village, pp 573-585
2. Andre FE (1984) Summary of clinical studies with the live attenuated varicella vaccine produced by Smith Kline-RIT. Biken J 27:89
3. Arbeter AM, Starr SE, Weibel RE, Neff BJ, Plotkin SA (1983) Live attenuated varicella vaccine: the KMeC strain in healthy children. Pediatrics 71:307-312
4. Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, Zelson CM, Proctor EA, Plotkin SA (1984) Varicella vaccine trials in healthy children: a summary of comparative and follow-up studies. Am J Dis Child 138:434-438
5. Arbeter A, Starr SE, Plotkin SP (1986) Varicella vaccine in healthy children and adults. Pediatrics 78:748-756
6. Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S, Tsuzuki K, Ito S, Isomura S, Takahashi M (1977) Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 59:3-7
7. Asano Y, Hirose S, Iwayama S, Miyata T, Yazaki T (1982) Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken J 25:43-35
8. Asano Y, Albrecht P, Vujcic LK, Quinnan GV Jr, Kawakami K, Takahashi M (1983) Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 72:291-294
9. Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, Takahashi M (1984) Persistence of protective immunity after inoculation with live varicella vaccine (strain Oka). Biken J 27:123
10. Asano Y, Nagai T, Miyata T, Kazaki T, Ho S, Kamanishi K, Takahashi M (1985) Long-term protective immunity of recipients of the OKA strain of varicella vaccine. Pediatrics 75:667-671
11. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S (1994) Experience and reason: twenty-year follow-up of protective immunity of the OKA strain live varicella vaccine. Pediatrics 94:524-526
12. Austgulen R (1985) Immunization of children with malignant diseases with the Okastrain varicella vaccine. Postgrad Med J [Suppl 4] 61:93-95
13. Balfour HH Jr, Suarez CS, Gilmore B, Bean B, Edelman CK, Amren DP (1985) Varicella vaccine trial in normal children: immunogenicity and side effects. Clin Res 33:885A
14. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ (1993) Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck vaccine. Pediatrics 92:833-837
15. Brunell PA, Geiser C, Shehab Z, Waugh JE (1982) Administration of live varicella vaccine to children with leukemia. Lancet 1:1069-1072
16. Brunell PA,Taylor-Wiedeman J, Shehab ZM, Geiser C, Firerson LS, Cobb EK (1984) Administration of varicella vaccine to children with leukemia. Biken J 27:83-88
17. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E (1986) Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77:53-55
18. CDC (1996) Prevention of varicella: Recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report 45, No.RR-11:1-36
19. CDC (1997) Outbreak of invasive group A streptococcus associated with varicella in a childcare center - Boston, Massachusetts. Morbidity and Mortality Weekly Report 46, No.40:944-948
20. Choo PW, Donahue JG, Manson JE, Platt R (1995) The epidemiology of varicella and its complications. J Infect Dis 172:706-712
21. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM (1995) Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 14:874-879
22. Doctor A, Harper MB, Fleisher GR (1995) Group A-hemolytic streptococcal bacteremia: historical overview, changing incidence and recent association with varicella. Pediatrics 96:428-433
23. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV, Harris J, Balfour HH (1991) A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 325:1539-1544
24. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M (1994) Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343:1548-1551
25. Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P, Ferrara A and the NIAID Varicella Vaccine Collaborative Study Group (1984) Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 252:355-362
26. Gershon AA, Steinberg S, Gelb L, Galasso G, Borkowsky W, LaRussa P, Ferrara A and the NIAID Varicella Vaccine Collaborative Study Group (1985) A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission. Postgrad Med J [Suppl 4] 61:73-78
27. Gershon AA, Steinberg SP, Gelb L and the NIAID Varicella Vaccine Collaborative Study Group (1986) Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics [Suppl] 78:757-762
28. Gershon AA, Steinberg SP, Larussa P, Ferrara A, Hammerschlag M, Gelb L (1988) Immunization of healthy adults with live attenuated varicella vaccine. J Infekt Dis 158:132-137
29. Gershon AA, Steinberg SP, and the Varicella Vaccine Collaborative Study Group of the National Institute of Allergy and Infectious Diseases (1989) Persistence of immunity to varicella in children with leukemia immunized with live varicella vaccine. N Engl J Med 320:892-897
30. Gershon AA, Steinberg SP, NIAID Collaborative Varicella Vaccine Study Group (1990) Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J Infect Dis 161:661-666
31. Gershon AA (1990) Chickenpox, measles and mumps. In: Remington JS, Klein JO (eds) Infectious diseases of the fetus and newborn infant. Saunders, Philadelphia, pp 395-445
32. Gershon AA, LaRussa P, Steinberg S (1991) Live attenuated varicella vaccine: current status and future uses. Semin Pediatr Infect Dis 2:171-178
33. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S (1992) Varicella vaccine: the American experience. J Infect Dis [Suppl 1] 166:563-568
34. Gershon AA (1992) Varicella vaccine: still at the crossroads. Pediatrics [Suppl] 90:144-148
35. Haas RJ, Belohradsky B, Dickerhoff R, Eichinger K, Eife R, Holtmann H, Goetz O, Graubner U, Peller P (1985) Active immunization against varicella of children with acute leukaemia or other malignancies on maintenance. Postgrad Med J [Suppl 4] 61:69-72
36. Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F (1998) Cellular immune response to a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine accepted for publication
37. Hardy I, Gershon A (1990) Prospects for use of a varicella vaccine in adults. Infect Dis Clin North Am 4:160-173
38. Hardy IB, Gershon AA, Steinberg SP, LaRuassa P and the Varicella Vaccine Collaborative Study Group (1991) The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med 325:1545-1550
39. Heidl M, Scholz H, Dörffel W, Wutzler P (1989) Varizellen und Zoster bei Kindern mit onkologischen Krankheiten. Z Ärztl Fortbd 83:133-135
40. Heller L, Berglund G, Ahström L, Hellstrand K, Wahren B (1985) Early results of a trial of the OKA-strain varicella vaccine in children with leukaemia or other malignancies in Sweden. Postgrad Med J [Suppl 4] 61:79-83
41. Hope-Simpson RE (1965) The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58:9-20
42. Horiuchi K (1984) Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978-1982. Biken J 27:51-58
43. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML (1988) Live attenuated varicella vaccine in healthy 12-24 month-old children. Pediatrics 81:512-517
44. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ, Watson BA, Starr SE, Plotkin SA (1991) Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9:643-647
45. Lawrence R, Gershon A, Holzman R, Steinberg S, NIAID Varicella Vaccine Collaborative Study Group (1988) The risk of zoster in leukemic children who received live attenuated varicella vaccina. N Engl J Med 318:543-548
46. Levin DL, Hayward AR (1995) Decreased herpetic neuralgia in patients immunized with VZV vaccine. Second International Conference for VZV, 1995, July 6-8, Paris
47. Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, Wharton M, Washington AE (1994) Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271:375-381
48. Lin TY, Huang YC, Ning HC, Hsueh C (1997) Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 16:1162-1165
49. Meyers JD (1974) Congenital varicella in term infants: risks reconsidered. J Infect Dis 129:215-217
50. Miller E, Marshall R, Vurdien J (1993) Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 4:222-230
51. Preblud SR (1981) Age-specific risks of varicella complications. Pediatrics 68:14-17
52. Preblud SR, Orenstein WA, Koplan JP, Hinman AR (1985) A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 61:17-22
53. Ross AH, Lenchner E, Reitman G (1962) Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 267:369-376
54. Salzman MB, Sharrar G, Steinberg S, LaRussa P (1997) Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 131:151-154
55. Schmitt HJ, Beutel K, Schuind A, Knuf M, Wagner S, Müschenborn S, Bogaerts H, Bock HL, Clemens R (1997) Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus and tricomponent acellular pertussis vaccine at 14-28 months of age. J Pediatr 130:616-623
56. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Horiuchi K (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288-1290
57. Takahashi M, Kamiya H, Baba K, Ozaki T, Horiuchi K (1985) Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J [Suppl 4] 61:61
58. Triebwasser JH, Harris RE, Bryant RE, Rhoades ER (1967) Varicella pneumonia in adults: report of seven cases and a review of literature. Medicine 46:409-423
59. Van Loon F, Markowitz L, McQuillan G et al. (1993) Varicella seroprevalence in US population. In: American Society for Microbiology (eds) Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). American Society for Microbiology, Washington DC
60. Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174:S330-334
61. Vugia DJ, Peterson CL, Meyers HB, Kim KS, Arrieta A, Schlievert PM, Kaplan EL, Werner SB, Mascola L (1996) Invasive group A streptococcal infections in children with varicella in southern California. Pediatr Infect Dis J 15:146-150
62. Watson BM, Jeller PM, Ellis RW, Starr SE (1990) Cell-mediated immune responses after immunisation of healthy seronegative children with varicella vaccine: kinetics and specifity. J Infect Dis 162:794-799
63. Watson BM, Foster JA (1995) Appropriate use of varicella vaccine. Clin Immunother 4:197-206
64. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rotherberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB, Skolnick EM (1984) Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 310:1400-1415
65. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Mathews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calandra GB (1991) Varicella vaccine (VARIVAX) in healthy children and adolescent: results from clinical trials, 1987 to 1989. Pediatrics 87:604-610
66. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB (1992) Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 11:19-23
67. Zhang Y, Cosyns M, Levin MJ, Hayward AR (1994) Cytokine production in varicella zoster virus-stimulated limiting delution lymphocyte cultures. Clin Exp Immunol 98:128-133